Context
  • The Drug Controller General of India (DCGI) has granted market authorisation to Takeda Biopharmaceuticals India’s QDENGA (TAK-003), making it the first dengue vaccine approved in India.
  • The vaccine has been approved for the prevention of dengue disease in individuals aged 4 to 60 years.
  • The approval marks a significant milestone in India's efforts to reduce the burden of dengue, which remains one of the country's major vector-borne diseases.
QDENGA: INDIA’S FIRST DENGUE VACCINE explained for UPSC

ABOUT QDENGA (TAK-003)

  • QDENGA (TAK-003) is a live-attenuated tetravalent dengue vaccine developed by Takeda Biopharmaceuticals.
  • It is designed to provide protection against all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4).
  • The vaccine is administered as a two-dose regimen, with the second dose given three months after the first dose.
  • It can be administered irrespective of whether an individual has previously been infected with dengue.
  • Unlike some earlier dengue vaccines, QDENGA does not require pre-vaccination screening for prior dengue infection.

APPROVAL BY DGCI

  • The Drug Controller General of India (DCGI) is the national regulatory authority responsible for approving new drugs, vaccines, and medical devices in India.
  • The approval was granted after evaluation of extensive global and Indian clinical trial data demonstrating the vaccine's safety, efficacy, and immunogenicity.
  • The vaccine is approved for use in individuals aged 4–60 years.
CLINICAL TRIAL EVIDENCE The approval is based on Takeda's global clinical development programme, which included:
  • 19 Phase I, Phase II, and Phase III clinical trials.
  • More than 28,000 participants across dengue-endemic and non-endemic countries.
TIDES (DEN-301) Phase III Trial
  • Included over 20,000 participants from eight dengue-endemic countries.
  • Demonstrated:
    • 80.2% efficacy against virologically confirmed dengue 12 months after the second dose.
    • 90.4% efficacy against dengue-related hospitalization 18 months after vaccination.
    • 84.1% efficacy against hospitalization after 4.5 years.
    • Sustained protection against dengue disease and hospitalization over seven years across all four dengue virus serotypes.

GLOBAL STATUS

  • QDENGA has been approved in 43 countries across:
    • Asia.
    • Latin America.
    • Europe.
  • More than 32 million doses have been distributed through public and private immunization programmes.
  • The vaccine has received WHO prequalification.
  • It is recommended by the World Health Organization (WHO) for use in dengue-endemic regions with high transmission.
  • It has been incorporated into:
    • Brazil's National Immunization Programme.
    • Public vaccination programmes in Argentina, Colombia, and Indonesia.

ABOUT DENGUE

  • Dengue is a viral disease caused by the dengue virus (DENV), which belongs to the Flavivirus
  • It is transmitted primarily through the bite of infected Aedes aegypti mosquitoes, and to a lesser extent Aedes albopictus.
  • There are four distinct serotypes of the dengue virus:
    • DENV-1
    • DENV-2
    • DENV-3
    • DENV-4
  • Infection with one serotype provides lifelong immunity against that serotype but only temporary protection against the others.

SYMPTOMS

  • High fever.
  • Severe headache.
  • Muscle and joint pain.
  • Skin rash.
  • Nausea and vomiting.
  • In severe cases, dengue may progress to Dengue Hemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS), which can be life-threatening.

DENGUE BURDEN IN INDIA

  • India accounts for nearly one-third of the global dengue burden.
  • Reported dengue cases have increased almost eleven-fold over the past two decades.
  • The actual number of infections is believed to be significantly higher than officially reported due to underreporting and asymptomatic infections.
  • Dengue outbreaks occur mainly during and after the monsoon season because of increased mosquito breeding.

SIGNIFICANCE

  • The approval of India's first dengue vaccine represents a major advancement in the country's public health preparedness.
  • Vaccination can significantly reduce severe dengue cases and dengue-related hospitalizations.
  • The vaccine strengthens India's strategy for controlling vector-borne diseases.
  • It complements existing dengue prevention measures such as vector control, surveillance, and public awareness.
  • The availability of a vaccine is expected to reduce healthcare costs associated with recurrent outbreaks.
  • It contributes to improved health security in one of the world's largest dengue-endemic countries.

CHALLENGES

  • Ensuring affordable and equitable access to the vaccine across all regions remains essential.
  • Integrating the vaccine into India's immunization strategy will require careful planning.
  • Continued mosquito control measures remain necessary because vaccination alone cannot eliminate dengue transmission.
  • Public awareness regarding vaccine eligibility and continued preventive practices needs to be strengthened.
  • Continuous surveillance will be required to monitor vaccine effectiveness under real-world conditions.

WAY FORWARD

  • The Government should develop clear guidelines for the phased introduction of the dengue vaccine.
  • Vaccination should complement integrated vector management and public health surveillance.
  • Strengthening urban sanitation and mosquito breeding control remains critical.
  • Research on long-term vaccine effectiveness and disease surveillance should continue.
  • Public awareness campaigns should promote vaccination alongside preventive measures such as eliminating stagnant water and using personal protective measures.